Republican Congressman Tom Davis of Virginia, chair of the House Government Reform Committee, demanded answers from FDA acting commissioner Dr. Lester Crawford regarding drug safety monitoring and Vioxx issues.
Dr. Eric Topol criticized FDA for not investigating Vioxx heart problems earlier.
Concerns over Celebrex and similar drugs' heart risks grew.
FDA expert Dr. David Graham faced resistance over Vioxx safety findings.
Merck's withdrawal of Vioxx raised questions about FDA oversight.
The need for stricter drug testing and monitoring was emphasized.
The impact of drug advertising on consumer choices was highlighted amidst safety concerns.
Pfizer's Bextra also faced scrutiny for potential heart
